Recent Publications

Grohar PJ, Heise R, Wedekind MF, Ballman K, Mascarenhas L, DuBois SG, Maki RG, Boguslawski EA, Gedminas JM, Wilson ER, Thomas E, Segers B, Surrey LF, Ricker C, Klega K, Navid F, Lam GY, The S, Kaufman R, Roberts RD, Hayashi M, Mena E, Overman L, Peer C, Schmidt K, Diamond MS, Figg WD, Bagatell R, Liza Lindenberg M, Choyke PL, Crompton BD, Widemann BC, Glod JW, Laetsch TW, Reinke DK, Chugh R. Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial. Nat Med. 2026 Apr 16. doi: 10.1038/s41591-026-04340-7. Epub ahead of print. PMID: 41991689

Kaufman R, Flores G, Boguslawski EA, Kinn-Gurzo S, Chassé M, Beddows I, Adams M, Stout MC, Gaetano L, Lopez R, Veluvolu S, Fuller A, Kitchen-Goosen SM, Tolstyka ZP, Gedminas JM, Grohar PJ. Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription. Nat Commun. 2026 Feb 16;17(1):2844. doi: 10.1038/s41467-026-69488-9. PMID: 41698909; PMCID: PMC13021929.

Tolstyka ZP, Grohar PJ. Exploiting divergent mechanisms of trabectedin for bone tumors. Mol Ther Oncol. 2025 Mar 14;33(2):200959. doi: 10.1016/j.omton.2025.200959. PMID: 40151540; PMCID: PMC11937656.

Jess J, Sorensen KM, Boguslawski EA, Stout MC, Madaj ZB, Caiello BP, Pomaville M, Wilson ER, Kinn-Gurzo SS, Parker CC, Veluvolu SM, Brysgel TV, Kaufman R, Kitchen-Goosen SM, Gedminas JM, Grohar PJ. Cell Context is the third axis of synergy for the combination of ATR inhibition and cisplatin in Ewing sarcoma. Clin Cancer Res. 2024 Mar 20. doi: 10.1158/1078-0432.CCR-23-3063. Epub ahead of print. PMID: 38506712.